Hologic (NASDAQ:HOLX) Issues Q1 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its first quarter 2025 earnings guidance on Monday morning. The company provided EPS guidance of 1.000-1.030 for the period, compared to the consensus EPS estimate of 1.030. The company issued revenue guidance of $1.0 billion-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Stock Down 4.8 %

HOLX traded down $4.01 during trading on Tuesday, reaching $79.71. 1,370,348 shares of the stock were exchanged, compared to its average volume of 1,581,496. The stock’s 50 day moving average price is $81.06 and its two-hundred day moving average price is $78.08. Hologic has a twelve month low of $66.93 and a twelve month high of $84.67. The stock has a market cap of $18.51 billion, a P/E ratio of 27.10, a price-to-earnings-growth ratio of 2.98 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same period last year, the business posted $0.89 EPS. The business’s revenue was up 4.5% compared to the same quarter last year. Equities analysts expect that Hologic will post 4.09 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HOLX shares. Mizuho increased their target price on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. JPMorgan Chase & Co. increased their price target on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. Finally, Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.